

KYOWA KIRIN'S NEW MANUFACTURING FACILITY: SANFORD, NORTH CAROLINA

Building on our legacy of pioneering manufacturing advancements, Kyowa Kirin is planning to build a new state-of-the-art facility that will expand its global production capacity. This expansion underpins the projected growth of the company's research and development initiatives, specifically aimed at offering new hope for patients with unmet medical needs.

KYOWA KIRIN NORTH AMERICA (KKNA) AT A GLANCE

Kyowa Kirin (KEY-OH-Wah KEER-In) is a Global Specialty Pharmaceutical company focused on the discovery and delivery of medicines with life-changing value. Based in Japan, we have more than 70 years of history developing breakthrough innovations. KKNA is the fastest-growing region in the company and markets 3 first-in-class medicines across 3 disease areas - hematological cancers, rare diseases, and neurological conditions. Globally, our four Core Values of Commitment to Life, Innovation, Integrity, and Teamwork/Wa guide all our work and efforts to make a profound impact on patients' lives.

GLOBAL MANUFACTURING NETWORK

Our continued commitment to drug discovery and the development of novel medicines using new modalities - such as antibody drug conjugates (ADCs), bispecific antibodies, cell and gene therapies - requires us to expand and advance our manufacturing capabilities. The new Sanford facility is an investment in our long-term, global plan to strengthen operations and ensure a stable supply of high-quality clinical and commercial products, with the hope of bringing life-changing value to patients as soon as possible.

ABOUT THE SANFORD FACILITY

The company has announced plans for a new facility to be located in Sanford, NC. The site will leverage the latest technologies to support the manufacturing of biologic products for targeted clinical and commercial use. Adding this facility to our global manufacturing footprint will expand global capacity, create more resilient and efficient supply lines, and support the training and development of our global manufacturing workforce with an additional center of excellence for biologics manufacturing.

"We will incorporate industry best practices, automation and the latest digital technologies at this facility creating advanced capabilities and a Center of Excellence for training our global manufacturing workforce."

Paul Testa,

Executive Vice President, Head of Supply Chain and Manufacturing, North America

FAST FACTS

75 acres of land in Sanford, North Carolina – to be part of planned Helix Innovation Park

100+ new, local jobs

expected to add across a range of functions, including engineering, manufacturing, quality assurance, quality control, finance and corporate function

3-4 years

Anticipated timeline to design, build, and complete construction. A flexible site master plan will allow for future site expansion and the addition of new capabilities as our pipeline and portfolio evolve.

COLLABORATING TO INNOVATE

Within our walls and across our industry, collaboration is the way Kyowa Kirin does business. Our history of innovation is built on forming and fostering collaborations to accelerate the delivery of new science and heighten our impact.

Innovation is not just about science. It's also about finding new ways to strengthen communities, engage customers, support patients, and empower the health care system to provide optimal care.

Here's how we're partnering, today and in the future:

- Community and scientific collaborations
- Business development and licensing
- Advocacy and public affairs
- Access, reimbursement and patient support service



President, North America Steve Schaefer



Executive Vice President, Head of Supply Chain and Manufacturing, North America Paul Testa, MS, MBA



Global President and Chief Executive Officer Masashi Miyamoto, Ph.D.

KKNA Website

kkna.kyowakirin.com/what-we-do/ operations/#manufacturing

LinkedIn /kyowa-kirin-inc.--u.s.

KKNA Headquarters

510 Carnegie Center Princeton, NJ 08540 X @KyowaKirin_US

YouTube @kyowakirinnorthamerica4433

Tokyo Stock Exchange Listing TSE: 4151

